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To characterize human herpesvirus 8 (HHV-8) gB, the open reading frame was PCR amplified from the HHV-8-infected cell
line BCBL-1 and cloned into an expression vector. To facilitate detection of expressed HHV-8 gB, the cytoplasmic tail of the
glycoprotein was tagged with the influenza hemagglutinin (HA) epitope. Expression of tagged HHV-8 gB (gB-HA), as well as
the untagged form, was readily detected in CHO-K1 cells and several lymphoblastoid cell lines (LCLs). HHV-8 gB-HA was
sensitive to endoglycosidase H treatment, and immunofluorescence revealed that HHV-8 gB-HA was detectable in the
perinuclear region of CHO-K1 cells. These observations suggest that HHV-8 gB is not processed in the Golgi and localizes
to the endoplasmic reticulum or nuclear membrane. Because both HHV-8 and EBV are g-herpesviruses, the ability of HHV-8
gB to interact with and functionally complement EBV gp110 was examined. HHV-8 gB-HA and EBV gp110 co-immunopre-
cipitated, indicating formation of hetero-oligomers. However, HHV-8 gB-HA and HHV-8 gB failed to restore the infectivity of
gp110-negative EBV mutants. These findings indicate that although HHV-8 gB and EBV gp110 have similar patterns of
intracellular localization and can interact, there is not sufficient functional homology to allow efficient complementation.
© 1998 Academic Press
INTRODUCTION
Herpesvirus infection is initiated by attachment to a
susceptible cell followed by a cascade of interactions
between viral glycoproteins and the plasma membrane
that ultimately results in penetration of the nucleocapsid
into the cytoplasm (reviewed in Spear, 1993; Cooper,
1994). For Epstein–Barr virus (EBV), the interaction of
gp350/220 with CD21, a receptor for the complement
component C3 days, mediates initial binding (Nemerow
et al., 1987, 1989; Tanner et al., 1987, 1988). Glycoprotein
350/220 has no known homolog in any of the other
herpesviruses examined to date. Subsequent penetra-
tion is mediated in part by gp350/220 (Nemerow and
Cooper, 1984; Tanner et al., 1987) and by a complex of
viral glycoproteins containing gp85, gp25, and gp42 (Hei-
neman et al., 1988; Miller and Hutt-Fletcher, 1988, 1992;
Haddad and Hutt-Fletcher, 1989; Yaswen et al., 1993;
Hutt-Fletcher, 1995; Li et al., 1995). EBV gp85 and gp25
are homologues to herpes simplex virus (HSV) gH and
gL, respectively (Baer et al., 1984; Heineman et al., 1988;
Yaswen et al., 1993). EBV gp42, which has no homolog in
HSV, is required for viral entry into B cells but not epi-
thelial cells (Li et al., 1995). Recently, a third protein that
interacts with human cytomegalovirus (HCMV) gH and
gL has been identified (Huber and Compton, 1997; Li et
al., 1997). Interestingly, EBV gp110, the HSV gB homolog,
appears to be essential for viral assembly (Herrold et al.,
1996; Lee and Longnecker, 1997). In contrast, HSV gB is
required for viral penetration (Manservigi et al., 1977;
Sarmiento and Spear, 1979; Cai et al., 1988) and can
mediate binding to cellular glycosaminoglycans if HSV
gC, the principal glycoprotein that mediates initial attach-
ment (Herold et al., 1991), is not expressed (Herold et al.,
1994). HSV gB does not appear to be required for viral
egress.
Glycoprotein B shows considerable homology among
the known herpesviruses, especially in the carboxyl-
terminal tail domain and in the relative positions of cys-
teine and proline residues (Ross et al., 1989; Goltz et al.,
1994; Pereira, 1994). All gB glycoproteins tested are es-
sential for herpesvirus infectivity. Engineered herpesvi-
rus mutants that do not express gB are not infectious in
the absence of complementation (Cai et al., 1987; Rauh
and Mettenleiter, 1991; Miethke et al., 1995; Herrold et al.,
1996). Cross-complementation between a-herpesvirus
gB glycoproteins can occur but is not always reciprocal.
For example, both bovine herpesvirus 1 (BHV-1) and
pseudorabies virus (PrV) gB may function in HSV-1 infec-
tivity (Misra and Blewett, 1991; Mettenleiter and Spear,
1994). However, BHV-1 gB (Rauh et al., 1991; Kopp and
Mettenleiter, 1992) but not HSV-1 gB (Mettenleiter and
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Spear, 1994) can complement gB-negative PrV while PrV
gB cannot complement gB-negative BHV-1 (Miethke et
al., 1995). By studying hybrid proteins composed of PrV
gB and BHV-1 gB domains, the carboxyl-terminal portion
of BHV-1 gB was found to be essential in restoring
infectivity to gB-negative BHV-1 (Miethke et al., 1995).
Recently it was shown that, despite significant amino-
acid homology, HSV gB and HCMV gB could not com-
plement the infectivity of gp110-negative EBV mutants
(Lee et al., 1997). However, differences in the cellular
localization or in the function of HSV gB and HCMV gB
when compared to EBV gp110 may not precluded effi-
cient complementation (Lee et al., 1997). Substantial dif-
ferences in cellular processing and localization and in
the ability to detect gB in virions exist. For example, EBV
gp110 is sensitive to endoglycosidase H treatment, im-
plying high-mannose N-linked glycosylation consistent
with gp110 localizing predominantly to the endoplasmic
reticulum and nuclear membrane (Qualtiere and Pear-
son, 1979; Emini et al., 1987; Gong et al., 1987; Gong and
Kieff, 1990). In contrast, HSV gB and HCMV gB are
processed in the Golgi and are readily detectable in the
plasma membrane as well as the endoplasmic reticulum
and nuclear membrane (Johnson and Spear, 1982; Britt
and Vugler, 1989; Pereira et al., 1989; Zheng et al., 1996).
In addition, EBV gp110 is not a major component of the
virion envelope (Gong et al., 1987; Gong and Kieff, 1990)
while both HSV gB and HCMV gB are readily detectable
in virions (Spear, 1976; Britt, 1984; Gretch et al., 1988;
Pereira, 1994).
Functionally, EBV gp110 appears to be essential for
viral envelopment (Herrold et al., 1996; Lee and Long-
necker, 1997) while HSV gB appears to be required for
entry. It is not known if EBV gp110 is required for viral
entry. HCMV gB is similar to HSV gB in that this glyco-
protein appears to be required for viral penetration (Na-
varro et al., 1993) and has heparin-binding activity (Kari
and Gehrz, 1992; Compton et al., 1993). Soluble HCMV
gB binds to cells, implying that HCMV gB may mediate
viral attachment to susceptible cells by interaction with
cellular components, possibly heparan sulfate (Boyle
and Compton, 1998).
Glycoprotein B from a closely related herpesvirus that
is processed and expressed similarly to EBV gp110 may
allow at least partial functional complementation of
gp110-negative EBV. Both human herpesvirus 8 (HHV-8)
and EBV are g-herpesviruses, although the former is
classified as a member of the Rhadinovirus genus
(Moore et al., 1996) while the latter is a member of the
Lymphocryptovirus genus (Rickinson and Kieff, 1996). In
addition, both viruses infect B lymphocytes (Ambroziak et
al., 1995; Rickinson and Kieff, 1996), and, as illustrated in
Fig. 1, HHV-8 gB shows 62.1% similarity and 42.6% iden-
tity to EBV gp110 (Russo et al., 1996). The gB homologues
from three other g-herpesviruses, bovine herpesvirus 4,
and equine herpesviruses 2 and 5, appear to be pro-
cessed and expressed more similarly to HSV gB than
EBV gp110 (Agius et al., 1994; Lomonte et al., 1997). In
contrast, murine herpesvirus 68 (MHV-68) gB is pro-
cessed and expressed similarly to EBV gp110. MHV-68
gB is glycosylated with high mannose N-linked glycans,
localizes predominantly to the cytoplasm and perinu-
clear regions, and is not readily detected in virions
(Stewart et al., 1994).
The current studies analyzed the intracellular process-
ing and expression of HHV-8 gB and assessed whether
HHV-8 gB can complement gp110-negative EBV mutants.
The cellular processing and expression of HHV-8 gB was
similar to that previously described for EBV gp110 and
the two glycoproteins formed hetero-oligomers in vitro.
However, there was insufficient functional homology be-
tween HHV-8 gB and EBV gp110 to allow efficient
complementation.
RESULTS
Construction of HHV-8 gB expression vectors
The predicted HHV-8 gB open reading frame encodes
a protein 845 amino acids in length (Russo et al., 1996).
This open reading frame was PCR amplified in two in-
dependent reactions from the HHV-8-infected cell line
BCBL-1, and both products were cloned into the expres-
sion vector pSG5. Sequencing of both amplified gB open
reading frames revealed the presence of two silent nu-
cleotide substitutions at positions 1705 (T to C) and 2881
(C to T) when compared to the previously published
sequence derived from the HHV-8-infected cell line BC-1
(Russo et al., 1996). To facilitate detection of expressed
HHV-8 gB, the cytoplasmic tail of the glycoprotein was
tagged with the hemagglutinin (HA) epitope, which is
recognized by the 12CA5 monoclonal antibody. The HA-
tagged gB construct (gB-HA) was deleted for the last four
amino acids (Glu-Thr-Gly-Glu) in the wild-type glycopro-
tein and contained three new amino acids (Ala-Glu-Phe)
prior to the HA epitope (Fig. 1).
Glycosylation and oligomerization of HHV-8 gB
Expression of HHV-8 gB-HA was readily detected in
CHO-K1 cells after immunoblotting with the anti-HA an-
tibody (data not shown). Human plasma was used to
detect the expression of untagged HHV-8 gB and to
confirm the expression of HHV-8 gB-HA. Briefly, gB-HA
was immunoprecipitated with anti-HA and used to
screen human plasma specimens obtained from the
Multicenter AIDS Cohort Study (data not shown). Plasma
obtained from one person 12 months after the diagnosis
of Kaposi’s sarcoma was found to be repeatedly reactive
against the immunoprecipitated gB-HA. As shown in Fig.
2A, both the untagged and tagged forms of HHV-8 gB
were readily detected in CHO-K1 cells after immunoblot-
ting with this human plasma. The untagged HHV-8 gB
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(lane 2) migrated at ;120 kDa while the tagged version
(lane 3) was slightly larger due to the addition of 10
amino acids.
Computer-assisted analysis (PCGene and Omiga) of
the predicted amino-acid sequence of HHV-8 gB re-
vealed three potential hydrophobic domains (amino ac-
ids 7–24, 706–729, and 733–752) (Argos et al., 1982). The
initial 23 amino acids are most likely a cleavable signal
sequence (Perlman and Halvorson, 1983; von Heijne,
1984). Cleavage at a potential signal peptidase site lo-
cated immediately following the consensus Ala-X-Ala
(where X corresponds to any amino acid) sequence
would yield a core protein 822 amino acids in length.
Thus the predicted molecular weights of mature core
HHV-8 gB and HHV-8 gB-HA would be 91.3 and 92.5 kDa,
respectively. The expressed proteins, however, had ap-
parent molecular weights of ;120 kDa (Fig. 2A), consis-
tent with HHV-8 gB undergoing glycosylation. Thirteen
potential N-linked glycosylation sites (Asn-X-Thr/Ser mo-
tif where X corresponds to any amino acid except pro-
line, which substantially lowers the efficiency of glyco-
sylation) are predicted in the protein sequence of HHV-8
gB (Marshall, 1972; Bause, 1983; Gavel and von Heijne,
1990).
To investigate the glycosylation pattern of HHV-8 gB,
the effects of N-glycosidase F and endoglycosidase H
treatment were studied. As shown in Fig. 2B, the 120-kDa
HHV-8 gB-HA protein was reduced to 95 kDa after either
FIG. 1. Predicted amino-acid sequence of HHV-8 gB, EBV gp110, and HSV-1 gB. The amino-acid sequences for HSV-1 (KOS) gB and EBV (B95–8)
gp110 were based on nucleotide sequences obtained from published reports (Baer et al., 1984; Bzik et al., 1984; Pellett et al., 1985a). The amino-acid
sequence for HHV-8 gB based on the nucleotide sequence obtained in these studies did not differ from that previously published (Russo et al., 1996).
Predicted N-linked glycosylation sites (double underline) and conserved cysteine (asterisks) and proline residues (filled circles) are shown. The
conserved CY(S/A)RP sequence along with the potential signal peptidase and furin-mediated proteolytic cleavage sites are indicated in bold italics.
Also shown is a shorter sequence of HHV-8 gB-HA that highlights the amino-acid changes resulting from addition of the HA-epitope. The HA-epitope
is indicated with a single underline. The HHV-8 gB nucleotide sequence from the BIBL-1 cell-line was deposited with GenBank (Accession No.
AF092928).
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N-glycosidase F (lane 2) or endoglycosidase H (lane 3)
treatment. These results suggest HHV-8 gB is glycosyl-
ated with high-mannose N-linked oligosaccharides that
are not subsequently modified in the Golgi, similar to
results previously described for EBV gp110 (Gong et al.,
1987; Gong and Kieff, 1990).
In infected cells and in the viral envelope, HSV gB
forms homodimers resistant to dissociation by SDS but
sensitive to dissociation by heat (Sarmiento and Spear,
1979; Haffey and Spear, 1980; Claesson-Welsh and
Spear, 1986). To determine whether HHV-8 gB forms
oligomers, HHV-8 gB-HA expressed in CHO-K1 cells was
immunoprecipitated with anti-HA. After elution with 3 M
potassium thiocyanate and dialysis against 10 mM
NH4HCO3-0.01% SDS, the purified HHV-8 gB-HA samples
were electrophoresized and then transferred to nitrocel-
lulose for immunoblotting. As shown in Fig. 2C, a signif-
icant fraction of unheated HHV-8 gB-HA migrated as
oligomers (lane 1), although adding 2-mercaptoethanol
to the samples decreased the relative amounts detected
(lanes 2 and 3). Heating HHV-8 gB-HA without adding
2-mercaptoethanol had little effect on the amounts of
oligomers detected (lane 4). In the samples heated in the
presence of 2-mercaptoethanol, however, most of the
slowly migrating bands disappeared (lanes 5 and 6).
These results indicate that HHV-8 gB forms oligomers
and that oligomerization requires disulfide bonds.
Intracellular localization of HHV-8 gB
The intracellular localization of HHV-8 gB was studied
by immunofluorescence in CHO-K1 cells following trans-
fection of the expression constructs of interest. As
shown in Fig. 3, HHV-8 gB-HA localized to the perinu-
clear region of the cells but no apparent movement to the
periphery was noted. A similar pattern of expression was
noted for EBV gp110, consistent with the retention of EBV
gp110 in the endoplasmic reticulum and nuclear mem-
brane (Qualtiere and Pearson, 1979; Emini et al., 1987;
Gong et al., 1987; Gong and Kieff, 1990). In contrast, the
pattern noted for HSV gB is different in that HSV gB
staining extended to the edges of each cell. This is
consistent with previous reports that HSV gB is ex-
pressed in the plasma membrane as well as in the
endoplasmic reticulum and nuclear membrane (Pereira
et al., 1989).
The lack of apparent movement of HHV-8 gB-HA to the
periphery of the cell and the glycoprotein’s sensitivity to
endoglycosidase H treatment is consistent with HHV-8
gB not trafficking through the Golgi but rather being
retained in the endoplasmic reticulum and nuclear mem-
brane. Amino-acid sequence analysis of the cytoplasmic
tail of HHV-8 gB revealed numerous lysines and argi-
nines (Fig. 1), including a Lys-Lys-X-X motif (where X
corresponds to any amino acid), that may be essential for
FIG. 2. Expression, glycosylation, and oligomerization of HHV-8 gB. (A) CHO-K1 cells were transfected with HHV-8 gB (lane 2), HHV-8 gB-HA (lane
3), or control expression vectors (lane 1). Twenty-four hours later, the cells were harvested, solubilized, boiled, and electrophoresized on a 7%
polyacrylamide prior to transfer to nitrocellulose for immunoblotting. Plasma (diluted 1:1000) obtained from a Kaposi’s sarcoma patient enrolled in the
Multicenter AIDS Cohort Study and previously shown to react to immunoprecipitated HHV-8 gB-HA (data not shown) was used for immunoblotting.
The plasma was preabsorbed with a lysate of CHO-K1 cells transfected with the control vector (pSG5). (B) CHO-K1 cells were transfected with the
HHV-8 gB-HA expression vector. The cells were solubilized 24 h later and HHV-8 gB-HA was immunoprecipitated with anti-HA. Immune-complexes
were subsequently collected by adding protein G Sepharose. Immunoprecipitated HHV-8 gB-HA was denatured by heating with 0.5% SDS and 1%
2-mercaptoethanol. Carbohydrate modifications were determined by incubating overnight at 37°C with 1 mU of endoglycosidase H (endo H; lane 3)
in 50 mM sodium citrate (pH 5.5) or with 200 mU of N-glycosidase F (PNGase F; lane 2) in 1% NP-40 and 50 mM sodium phosphate (pH 7.5) or without
added enzyme (lane 1). Western blots of control and glycosidase treated samples were immunoblotted with anti-HA. (C) Immunoprecipitated HHV-8
gB-HA was eluted with 3 M potassium thiocyanate (pH 7.1) and dialyzed against 10 mM NH4HCO3-0.01% SDS. Prior to electrophoresis, samples were
prepared as follows. Unheated samples in the absence and presence of 2-mercaptoethanol (1% or 3.5% 2-ME) were loaded in lanes 1, 2, and 3 while
heated (boiled for 5 min) samples in the absence and presence of 2-mercaptoethanol were loaded in lanes 4, 5, and 6. All samples were kept on
ice except when heated.
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retention of the glycoprotein in the endoplasmic reticu-
lum or nuclear membrane (reviewed in Teasdale and
Jackson, 1996). However, the di-lysine motif is not near
the carboxyl terminus, an apparent requirement for this
sequence to function as a retention signal.
Co-immunoprecipitation of HHV-8 gB and EBV gp110
Because both HHV-8 gB and EBV gp110 are g-herpes-
viruses and appear to have similar patterns of cellular
localization, the ability of the two glycoproteins to form
hetero-oligomers was tested. CHO-K1 cells were trans-
fected with one of three combinations: (i) HHV-8 gB-HA
and EBV gp110 expression vectors, (ii) EBV gp110 and
control expression vectors, or (iii) HHV-8 gB-HA and
control expression vectors. Cell lysates were subse-
quently immunoprecipitated with either an anti-HA anti-
body or an anti-gp110 antibody. The resulting immune
complexes were electrophoresized and then transferred
to nitrocellulose for immunoblotting with anti-HA or anti-
EBV human serum.
As shown in Fig. 4, EBV gp110 was detected in the
anti-HA immunoprecipitate derived from cells trans-
fected with both HHV-8 gB-HA and EBV gp110 (Fig. 4A,
lane 1). Similarly, HHV-8 gB-HA was detected in the
anti-gp110 immunoprecipitate derived from cells trans-
fected with both glycoproteins, albeit at a lower level
(Fig. 4B, lane 4). Thus HHV-8 gB-HA and EBV gp110
co-immunoprecipitated, implying formation of hetero-oligo-
mers. These results could not be explained by immuno-
genic cross-reactivity between HHV-8 gB and EBV gp110
because no EBV gp110 was detected after immunopre-
cipitation with anti-HA (Fig. 4A, lane 2) and no HHV-8
gB-HA was detected after immunoprecipitation with anti-
gp110 (Fig. 4B, lane 6). As expected, anti-HA did not
recognize immunoprecipitated EBV gp110 (Fig. 4B, lane
5) and anti-EBV human serum did not recognize immu-
noprecipitated HHV-8 gB-HA (Fig. 4A, lane 3).
Similar experiments using cells transfected with
HHV-8 gB-HA and HSV gB expression vectors showed
that these two glycoproteins did not form hetero-oligo-
mers to any significant extent. Although not visible in Fig.
4, a low level of HSV gB could be detected by an anti-
HSV gB immunoblot using R-74 after immunoprecipitat-
ing glycoproteins with anti-HA from cells transfected with
both HHV-8 gB-HA and HSV gB (Fig. 4C, lane 1). How-
ever, no HHV-8 gB-HA was detected by anti-HA after
immunoprecipitating glycoproteins with the anti-HSV gB
antibody II-105 (Fig. 4D, lane 4). The inability of HHV-8 gB
and HSV gB to co-precipitate implies that the noted
interaction between HHV-8 gB and EBV gp110 is specific
and not the result of aggregation.
Complementation analysis of gp110-negative EBV-
infected LCLs with HHV-8 gB
Because the two glycoproteins can form hetero-oligo-
mers, the ability of HHV-8 gB to functionally complement
EBV gp110 was examined. To this end, gp110-negative
and -positive EBV-infected LCLs were transfected with
FIG. 3. Intracellular localization of HSV gB, EBV gp110, and HHV-8
gB-HA. CHO-K1 cells were transfected with expression vectors containing
the indicated glycoproteins. Twenty-four hours after transfection, the cells
were fixed and then incubated with monoclonal antibodies reactive with
the indicated glycoproteins. II-105, VCA125, and anti-HA were used to
detect HSV gB, EBV gp110, and HHV-8 gB-HA, respectively. Cells trans-
fected with the vector control were incubated with anti-HA. After subse-
quent incubation with species specific fluorescein isothiocyanate- or in-
docarbocyanine-conjugated immunoglobulin G, cells were visualized us-
ing a Zeiss fluorescence photomicroscope.
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EBV gp110, HHV-8 gB, or HHV-8 gB-HA expression vec-
tors. The expression of HHV-8 gB-HA was detected in
transfected lymphoblastoid cell lines (LCLs) (Fig. 5) while
expression of EBV gp110 has been demonstrated previ-
ously (Herrold et al., 1996). To induce lytic replication, the
LCLs were also transfected with pSVNaeZ (Swami-
nathan et al., 1991) and then cultured in media containing
TPA. Production of infectious virus was assessed by
culturing primary human B lymphocytes with lethally g-ir-
radiated transfected LCLs or cell-free culture superna-
tants and measuring subsequent EBV-induced transfor-
mation (Herrold et al., 1996).
As shown in Table 1, transfection of the gp110-positive
EBV-infected LCLs with any of the expression vectors
had no apparent effect on the frequency of EBV-induced
transformation. In contrast, only the gp110-negative EBV-
infected LCLs that were transfected with the EBV gp110
expression vector induced transformation of primary B
lymphocytes. The lack of transformation after transfec-
tion with HHV-8 gB or HHV-8 gB-HA expression vectors
indicates that there is not sufficient functional homology
between EBV gp110 and HHV-8 gB to allow efficient
complementation.
DISCUSSION
Glycoprotein B is the most conserved herpesvirus gly-
coprotein. Analysis of the HHV-8 gB protein sequence
(Fig. 1) reveals that HHV-8 gB shares structural features
and motifs with previously characterized herpesvirus gB
glycoproteins. HHV-8 gB most likely consists of three
domains. Two hydrophobic domains from amino acids
706–752 divide HHV-8 gB into a 93-amino-acid carboxyl
terminal tail and a large 705-amino terminal domain. As
described for HSV gB (Pellett et al., 1985b), the carboxyl-
terminal tail displays features consistent with a cytoplas-
mic domain in that this region is hydrophilic and posi-
FIG. 4. Co-immunoprecipitation of HHV-8 gB-HA, and EBV gp110. CHO-K1 cells were transfected with combinations of expression vectors
containing glycoproteins from the indicated viruses. A total of 2 mg of plasmid DNA (1 mg of each glycoprotein containing expression vector or vector
control) was used for each transfection. The cells were lysed 24 h after transfection, and the glycoproteins of interest were immunoprecipitated.
Anti-HA was used for the immunoprecipitations loaded in lanes 1–3 of all four panels. Anti-EBV-gp110 was used for lanes 4–6 of (A) and (B) while
anti-HSV-1-gB was used for lanes 4–6 of (C) and (D). The immunoprecipitated proteins were separated by 10% SDS–PAGE and transferred to
nitrocellulose for subsequent immunoblotting. Proteins were detected with anti-EBV human serum (A), anti-HA (B and D), or R-74 rabbit serum (C).
FIG. 5. Expression of HHV-8 gB-HA in LCLs. LCL-1, LCL-2, and
LCL-10 contain wild-type EBV while 6.16, KC.1, and M.2 contain gp110-
negative EBV mutants. Cells were electroporated with the vector con-
trol or the expression vector containing HHV-8 gB-HA. Cells were lysed
3 days after transfection and then the cleared lysates were immuno-
precipitated with the anti-HA monoclonal antibody. The immunoprecipi-
tated proteins were separated by 10% SDS–PAGE and transferred to
nitrocellulose for subsequent immunoblotting using anti-HA.
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tively charged. The initial 705 residues are most likely a
large ectodomain. This region is predominantly hydro-
philic, with 13 potential N-glycosylation sites and a pre-
dicted cleavable signal sequence. In addition, 10 cys-
teine residues previously shown to be highly conserved
among the known herpesvirus gB glycoproteins are
present (Ross et al., 1989; Goltz et al., 1994; Pereira,
1994). Interestingly, a highly conserved sequence (Cys-
Tyr-Ser-Arg-Pro) unique to herpesvirus gB glycoproteins
and of unknown function (Ross et al., 1989) is only par-
tially conserved in HHV-8 gB (Cys-Tyr-Ala-Arg-Pro). The
significance of this observation is unclear.
A proteolytic cleavage site (Arg-X-(Lys/Arg)-Arg-Ser),
where X can represent any amino acid) is predicted in
the HHV-8 gB protein sequence (Spaete et al., 1988).
HCMV, PrV, and BHV-1 gB all contain this site and are
cleaved during synthesis (Grose et al., 1984; Lukacs et
al., 1985; Montalvo and Grose, 1987; Spaete et al., 1988;
Whealy et al., 1990; Kopp et al., 1994). Cleavage of HCMV
gB is mediated by the human endoprotease furin (Vey et
al., 1995). In contrast, both EBV gp110 and HSV gB lack
this site and are not cleaved. Inhibition of HCMV gB
cleavage may impair release of progeny virus from in-
fected cells (Bru¨cher et al., 1990) while disrupting the
cleavage site in BHV-1 gB may impair cell to cell spread
of virus (Kopp et al., 1994). Interestingly, HHV-8 gB does
not appear to be cleaved. Under reducing conditions,
Western blots of transfected CHO-K1 lysates using hu-
man plasma for detection only identified bands at ;120
kDa for both HHV-8 gB and gB-HA (Fig. 2A). In addition,
TABLE 1
Transformants Obtained by Passage of gp110-Negative and gp110-Positive EBV Containing LCLs after Complementation with HHV-8 gB
Experimental group Cell line Experiment
Glycoprotein used for complementation
EBV gp110 HHV-8 gB HHV-8 gB-HA
Cocultivation
gp110-positive EBV LCLs LCL10 1 14 7 19
2 18 26 30
3 21 20 34
4 22 10 12
5 40 38 50
Total 115 101 145
gp110-negative EBV LCLs KC.1 1 0 0 0
2 1 0 0
3 0 0 0
4 0 0 0
5 28 0 0
Total 29 0 0
M.2 1 5 0 0
2 6 0 0
3 1 0 0
4 2 0 0
5 4 0 0
Total 18 0 0
Cell free
gp110-positive EBV LCLs LCL10 1 2 4 2
2 3 2 2
3 1 3 7
4 0 0 0
5 2 2 1
Total 8 11 12
gp110-negative EBV LCLs M.2 1 2 0 0
2 1 0 0
3 0 0 0
4 2 0 0
5 0 0 0
Total 5 0 0
Note. LCLs were transfected with plasmids containing the indicated glycoproteins. Three to 6 days posttransfection, primary human B lymphocytes
were co-cultivated with g-irradiated transfected LCLs or infected with cell-free virus. The number of wells positive for EBV transformants were scored
after 6–8 wk. Each transfection was plated onto one 96-well plate. Each line represents one experiment. The total number of clones obtained in each
experimental group is shown. Only clones from which the hygromycin phosphotransferase insert, but not the intact gp110 gene, could be detected
by PCR were counted (data not shown). No transformants resulted from infection of primary human B lymphocytes with gp110-negative EBV obtained
from LCLs transfected with the expression vector alone (data not shown).
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only 120-kDa bands were detected after immunoprecipi-
tating gB-HA from transfected LCLs (Fig. 5). The reason
for these observations is not clear but additional HHV-8
proteins may be required for proteolytic cleavage of
HHV-8 gB.
The relatively high degree of amino-acid and structural
homology among the known herpesvirus gB glycopro-
teins is consistent with an essential role for this glyco-
protein in viral infectivity. All gB glycoproteins tested are
required for infectivity in that engineered herpesvirus
mutants that do not express gB are not infectious in the
absence of complementation (Cai et al., 1987; Rauh and
Mettenleiter, 1991; Miethke et al., 1995; Herrold et al.,
1996). The high degree of homology among the gB gly-
coproteins implies that the gBs from different herpesvi-
ruses may have similar functions and that cross-comple-
mentation may be possible. Indeed, cross-complemen-
tation among a-herpesvirus gB glycoproteins can occur
but is not always reciprocal (Misra and Blewett, 1991;
Rauh et al., 1991; Kopp and Mettenleiter, 1992; Metten-
leiter and Spear, 1994; Miethke et al., 1995). However,
cross-complementation among the gB glycoproteins
from different subfamilies of herpesviruses appears to
be considerably less efficient. HSV gB and HCMV gB
failed to complement gp110-negative EBV while HCMV
gB and EBV gp110 failed to complement gB-negative
HSV (Lee et al., 1997). It may be that significant diver-
gence in gB structure and function among the herpesvi-
rus subfamilies may preclude complementation.
The results presented here demonstrate that HHV-8
gB and EBV gp110 appear to have similar patterns of
intracellular expression. HHV-8 gB was sensitive to en-
doglycosidase H treatment and localized to the perinu-
clear region of transfected cells. Although more definitive
localization studies are required, these observations
suggest that HHV-8 gB is retained in the endoplasmic
reticulum and nuclear membrane, a pattern similar to
that previously described for EBV gp110 (Qualtiere and
Pearson, 1979; Emini et al., 1987; Gong et al., 1987; Gong
and Kieff, 1990). In addition, HHV-8 gB and EBV gp110
co-immunoprecipitated, implying that the domains re-
quired for the oligomerization of HHV-8 gB may be con-
served in EBV gp110. Based on the results presented
here, the oligomerization of HHV-8 gB appears to require
disulfide bonds. For HSV gB, an essential site and a
nonessential site for oligomer formation have been iden-
tified (Highlander et al., 1991; Qadri et al., 1991; Navarro
et al., 1993; Laquerre et al., 1996). The essential site can
be further divided into two domains (residues 626–653
and 653–675) that are both sufficient for oligomerization
(Laquerre et al., 1996). However, the cysteine residues at
amino acids 596 and 633 do not appear to be required for
the formation of HSV gB dimers (Laquere et al., 1996).
With the noted similarities between HHV-8 gB and EBV
gp110, it was somewhat unexpected that HHV-8 gB was
unable to efficiently complement gp110-negative EBV.
This apparent lack of complementation could be attrib-
uted to several reasons. For one, differences in HHV-8
and EBV may prevent efficient complementation. Al-
though similarities in processing and cellular localization
suggest that HHV-8 gB and EBV gp110 may have similar
functions, no information is currently available on the
role of HHV-8 gB in viral infectivity. Also, additional EBV
glycoproteins essential for viral infectivity may not inter-
act with HHV-8 gB. If a well-coordinated cascade of
interactions between viral glycoproteins and the plasma
membrane is needed for efficient viral entry or egress,
formation of an entry or egress complex containing some
or all of the essential glycoproteins may be required.
Essential EBV glycoproteins, such as gp85 or gp25, may
be unable to functionally interact with HHV-8 gB.
The above results do not exclude the possibility that
HHV-8 gB may be able to complement gp110-negative
EBV but only partially. The complementation assay re-
quires the production of virus that can subsequently
enter and then transform primary B cells. Although EBV
gp110 appears to be essential for viral assembly (Herrold
et al., 1996; Lee and Longnecker, 1997), the possibility
that gp110 mediates viral entry into cells has not been
excluded and is a reasonable assumption based on the
known functions of other herpesvirus gB glycoproteins.
HHV-8 gB may be able to complement assembly or entry
of gp110-negative EBV but not both. EBV gp110 is not
required for transformation of primary B cells (Herrold et
al., 1996). Similarly, HHV-8 gB may be able to completely
complement gp110 but at an efficiency below the sensi-
tivity of the complementation assay. Future studies de-
signed to investigate the functional role of HHV-8 gB in
viral infectivity may help to delineate some of these
possibilities.
In conclusion, the cellular expression of HHV-8 gB was
similar to that previously described for EBV gp110. In
addition, HHV-8 gB and EBV gp110 co-immunoprecipi-
tated, implying the formation of hetero-oligomers. How-
ever, there was insufficient functional homology between
HHV-8 gB and EBV gp110 to allow efficient complemen-
tation of gp110-negative EBV mutants.
MATERIALS AND METHODS
Cells and viruses
CHO-K1 cells (American Type Culture Collection) were
passaged in medium F12 supplemented with 10% fetal
bovine serum (FBS) and antibiotics (penicillin and strep-
tomycin). BCBL-1 is a body-cavity-based lymphoma cell
line infected with HHV-8 (Renne et al., 1996) obtained
from the AIDS Research and Reference Reagent Pro-
gram. BCBL-1 cells were passaged in medium RPMI
1640 containing 10% FBS, 5 3 1025 M 2-mercaptoethanol
and antibiotics. All EBV-containing LCLs were passaged
in RPMI 1640 medium supplemented with 10% FBS and
antibiotics. Lymphoblastoid cell lines LCL-1, LCL-2, and
409EXPRESSION OF HHV-8 gB
LCL-10 contain wild-type EBV while 6.16, KC.1, and M.2
contain gp110-negative EBV mutants constructed by in-
serting hygromycin phosphotransferase into the NsiI en-
donuclease restriction site of the gp110 (BALF4) reading
frame (Herrold et al., 1996; Lee and Longnecker, 1997).
Antibodies
Monoclonal antibodies used were a mouse anti-EBV
gp110 antibody VCA125 (Chemicon), a mouse anti-HSV-1
gB antibody II 105 (Para et al., 1985), and a rat anti-
HA high affinity antibody (Boeringer-Mannheim). Poly-
clonal antibodies used were a rabbit anti-HSV-1 gB an-
tibody R-74 (Herold et al., 1994) and previously described
anti-EBV human serum (Herrold et al., 1996). R-74 was
preabsorbed by incubation at 4°C overnight with a gB-
negative HSV-1-infected cell lysate.
Amplification and cloning of viral DNA sequences
PCR was performed using Vent polymerase (New En-
gland Biolabs) and purified DNA isolated from BCBL-1 by
the Trizol Reagent kit (GibcoBRL). The HHV-8 gB open
reading frame was amplified using the BamHI endonu-
clease restriction site tagged sense primer gB-1 59-
TGAATTCATGACTCCCAGGTCTAGATTGGCC-39 and the
EcoRI tagged anti-sense primer gB-2 59-TTGGATCCGTC-
TGTGTGCAACGAGTAGG-39. (Northwestern University Bio-
technology Facility). Thermocycling reactions using a
PTC-100 programmable thermal controller (MJ Research)
consisted of a 35-cycle step-down protocol in which the
annealing temperature was sequentially lowered from
70°C by 3°C increments after every third cycle until a
final temperature of 55°C was reached. For each cycle,
the DNA was denatured at 94°C for 45 s and the PCR-
generated DNA fragment was extended at 72°C for
150 s. A final extension for 5 min at 72°C followed. All
PCR products were desalted and concentrated using the
QIAEX II gel extraction kit (Qiagen). PCR products were
subsequently cloned into the expression vector pSG5
(Stratagene). HHV-8 gB nucleotide sequences were de-
termined from both strands (University of Chicago Can-
cer Research Center DNA Sequencing Facility).
The cytoplasmic tail of HHV-8 gB was tagged with the HA
epitope as follows. Briefly, an EcoRI linker was ligated into
a blunted BspEI restriction site. The truncated gB open
reading frame was then subcloned into the EcoRI site of
pMN104 and screened for orientation. The vector pMN104
allows expression of HA-tagged proteins under control of
the HCMV immediate-early promoter (Novotny, 1996). The
HA-tagged gB construct (gB-HA) was excised by sequential
digestion with Bsp120I, large (klenow) fragment of DNA
polymerase I, and BamHI and then cloned into the BamHI
and blunted BglII sites of pSG5.
Transfections
Transfections into CHO-K1 cells were done using Li-
pofectamine Reagent (GibcoBRL). Briefly, subconfluent
CHO-K1 cells were overlaid with 1–2 mg of purified plas-
mid DNA and Lipofectamine reagent in OptiMEM (Gib-
coBRL) and incubated at 37°C for 8 h. After the transfec-
tion mixture was removed, complete F12 medium was
added, and the cells were incubated for 16 h at 37°C in
5% CO2. The cells were then harvested or processed for
subsequent experiments.
Transfections into LCLs were done by electroporation.
Briefly, 5–20 3 106 cells were resuspended in 400 ml
RPMI containing the plasmids of interest. The cells were
electroporated using a Gene Pulser electroporator (Bio-
Rad Laboratories). The cells were then transferred into
25-cm2 flasks containing medium RPMI 1640 and 20
ng/ml tetradecanoyl phorbol acetate (TPA; Sigma) and
subsequently incubated for 3–6 days at 37°C in 5% CO2.
Western blots
Cell lysates were solubilized in sodium dodecyl sulfate
(SDS) sample buffer, boiled for 5 min, and then loaded onto
a SDS–polyacrylamide (PAGE) gel (N,N9-methylene-bis-
acrylamide) (Bio-Rad Laboratories). Following electropho-
resis, the proteins were transferred to nitrocellulose
(Schleicher & Schuell) with a Trans-Blot electrophoretic
transfer cell apparatus (Bio-Rad Laboratories). The nitrocel-
lulose blot was incubated in blocking buffer and then se-
quentially with antibodies reactive against the antigen of
interest and species-specific alkaline phosphatase-conju-
gated antiimmunoglobulin G. Reactive bands were visual-
ized after incubation with chemiluminescence ECL sub-
strate (Amersham Life Sciences) and subsequent exposure
to autoradiography film (Amersham Life Sciences).
Immunoprecipitations
Cells were lysed with RIPA buffer containing protease
inhibitors for 30 min on ice. After centrifugation, the
cleared lysates were preaborbed with protein G sepha-
rose (Pharmacia Biotech) and then immunoprecipitated
with either anti-EBV gp110 VCA125 (2 mg/ml), anti-HSV
gB II-105 (diluted 1:100), or anti-HA (2 mg/ml) for 1–3 h at
4°C. The immune-complexes were collected by the ad-
dition of protein G Sepharose and then washed with lysis
buffer prior to further analysis.
Immunofluorescence
CHO-K1 cells were grown and transfected on micro-
scope slides and then fixed with a 1:1 mixture of acetone
and methanol for 5 min. After blocking with 20% goat
serum, cells were sequentially incubated with monoclo-
nal antibodies (diluted 1:500) reactive against the anti-
gens of interest and fluorescein isothiocyanate-conju-
gated goat anti-mouse (Pharmingen) or indocarbocya-
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nine-conjugated goat anti-rat (Jackson) immunoglobulin
G (diluted 1:500). Cells were subsequently observed by
using a Zeiss fluorescence photomicroscope.
Lymphocyte transformation assays
Primary human B lymphocytes were isolated by layering
whole blood over ficoll and then mixing the resulting buffy
coat cells with sheep red blood cells (Bectin Dickinson) to
rosette the T cells. As previously described (Herrold et al.,
1996), purified B cells were cocultivated with 1–3 3 104
g-irradiated (5000 rads) transfected LCLs or with cell-free
virus obtained from the lymphoblastoid culture supernatant.
Subsequently, 5–10 3 104 B cells were plated in each well
of 96-well dishes and incubated for 6–8 weeks at 37°C in
5% CO2. Wells with cell growth were visualized and the
presence of the hygromycin phosphotransferase insert and
the disruption of the gp110 gene in the newly obtained
lymphoblastoid cells verified by PCR as previously de-
scribed (Herrold et al., 1996).
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